BU
NVS icon

BBVA USA’s Novartis NVS Stock Holding History

BBVA USA’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$5.96M Sell
72,855
-2,955
-4% -$266K 0.35% 63
2021
Q2 		$6.92M Buy
+75,810
New +$6.75M 0.39% 56

Other funds holding NVS

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Aristotle Capital Management
Aristotle Capital Management Los Angeles, California $47.8B AUM 13.38% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

BBVA USA's NVS Position: Q3 2021 in Review

BBVA USA reduced its Novartis (NVS) stake by 3.9% in Q3 2021, selling an estimated $266K and leaving 72,855 shares worth $5.96M. The position accounts for 0.35% of the portfolio, ranked #63.

BBVA USA first reported a position in NVS in Q2 2021 and has held it in 2 quarters since. The position peaked at $6.92M in Q2 2021. 1,080 funds tracked by Wall St. Rank hold NVS as of Q3 2021.

  • BBVA USA held 72,855 shares of Novartis worth $5.96M as of Q3 2021.
  • BBVA USA sold 2,955 Novartis shares in Q3 2021, an estimated $266K.
  • Novartis made up 0.35% of BBVA USA's portfolio in Q3 2021, its #63 holding.
  • BBVA USA first reported a position in Novartis in Q2 2021 and has held it in 2 quarters since.
  • BBVA USA's Novartis position peaked at $6.92M in Q2 2021.
  • 1,080 funds tracked by Wall St. Rank held Novartis as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.